<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0864-0289</journal-id>
<journal-title><![CDATA[Revista Cubana de Hematología, Inmunología y Hemoterapia]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Hematol Inmunol Hemoter]]></abbrev-journal-title>
<issn>0864-0289</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0864-02892021000400022</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evolución del grado de control de una cohorte de pacientes anticoagulados de Atención Primaria]]></article-title>
<article-title xml:lang="en"><![CDATA[Evolution of the degree of control in a cohort of anticoagulated patients in Primary Care]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín Enguix]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hidalgo Rodríguez]]></surname>
<given-names><![CDATA[Abraham]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre Rodríguez]]></surname>
<given-names><![CDATA[Juan Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez Cambronero]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lacorzana]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Centro de Salud &#8220;Fortuny-Velutti&#8221;  ]]></institution>
<addr-line><![CDATA[ Granada]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Centro de Salud &#8220;Realejo&#8221;  ]]></institution>
<addr-line><![CDATA[ Granada]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Universitario &#8220;Virgen de las Nieves&#8221;  ]]></institution>
<addr-line><![CDATA[ Granada]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>37</volume>
<numero>4</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0864-02892021000400022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0864-02892021000400022&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0864-02892021000400022&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción: Solo el 60 % de los pacientes en tratamiento con antagonistas de la vitamina K (AVK) están controlados.  Objetivos: A nalizar una cohorte de pacientes anticoagulados para valorar su grado de control y su evolución a los 2 años, tras una intervención formativa breve.  Métodos: Estudio longitudinal, observacional, retrospectivo de 157 anticoagulados con AVK. Se recogieron datos sociodemográficos, comorbilidades, motivo de prescripción del AVK y grado de control basal y tras 2 años de seguimiento. Utilizamos 2 métodos de valoración diferentes: Rosendaal y método directo (porcentaje de INR-Razón Normalizada Internacional- en rango). Asimismo, establecimos correlaciones temporales intramétodo.  Resultados: El grado de control pasó del 47,3 % al 53,5 % a los 2 años, según Rosendaal (p= 0,52), y del 39,5 % al 53,5 % según el método directo (p&lt; 0,05). El tiempo en rango terapéutico fue del 63,1 ±19,9 % al inicio y 65 ±19,2 % al final del seguimiento. La correlación entre los 2 controles fue positiva para ambos métodos (Rosendaal: 0,23; método directo: 0,33). El análisis multivariante fue significativo para el sexo masculino y para un objetivo diferente de 2,5-3,5 (odds ratio: 2,22 y 2,73, respectivamente).  Conclusiones: El control del INR mejoró a los 2 años de seguimiento tras la actividad formativa. La evolución del grado de control de cada paciente es parcialmente predecible. El peor control se asoció al sexo femenino y al objetivo de INR de 2,5-3,5. El control mejora 2,22 veces en los varones y 2,73 veces en quienes no tienen un INR objetivo de 2,5-3,5]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction: Only 60% of patients on treatment with vitamin K antagonists (AVK) are controlled.  Objectives: We proposed to analyze a cohort of anticoagulated patients to assess their degree of control and their evolution at 2 years, after a brief training intervention.  Methods: Longitudinal, observational, retrospective study of 157 anticoagulated with AVK. Sociodemographic data, comorbidities, reason for VKA prescription and degree of baseline control were collected and after 2 years of follow-up. We use 2 different valuation methods: Rosendaal and direct method (INR percentage -International Normalized Ratio- in range). Likewise, we established intra-method temporal correlations.  Results: The degree of control went from 47.3% to 53.5% at 2 years, according to Rosendaal (p = 0.52), and from 39.5% to 53.5% according to the direct method (p&lt;0.05). The time in the therapeutic range was 63.1±19.9% at the start and 65±19.2% at the end of the follow-up. The correlation between the 2 controls was positive for both methods (Rosendaal: 0.23; direct method:0.33). The multivariate analysis was significant for males and for a target other than 2.5-3.5(odds ratio: 2.22 and 2.73, respectively).  Conclusions: INR control improved after 2 years of follow-up after training activity. The evolution of the degree of control of each patient is partially predictable. The worst control was associated with female sex and the INR goal of 2.5-3.5. Control improves 2.22 times in males and 2.73 times in those without a target INR of 2.5-3.5.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[atención primaria de salud]]></kwd>
<kwd lng="es"><![CDATA[anticoagulantes]]></kwd>
<kwd lng="es"><![CDATA[grado de control de INR]]></kwd>
<kwd lng="en"><![CDATA[primary health care]]></kwd>
<kwd lng="en"><![CDATA[anticoagulants]]></kwd>
<kwd lng="en"><![CDATA[INR control degree]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín Enguix]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aguirre Rodríguez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortalidad en una cohorte de pacientes de Atención Primaria tratados con anticoagulantes antagonistas de la vitamina K]]></article-title>
<source><![CDATA[Medicina Clínica]]></source>
<year>2021</year>
<volume>157</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>427-33</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altiok]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Marx]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral Anticoagulation]]></article-title>
<source><![CDATA[DtschArztebl Int]]></source>
<year>2018</year>
<volume>115</volume>
<numero>46</numero>
<issue>46</issue>
<page-range>776-83</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fawzy]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Lip]]></surname>
<given-names><![CDATA[GYH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation]]></article-title>
<source><![CDATA[Expert Opin Drug Metab Toxicol]]></source>
<year>2019</year>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>381-98</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Llisterri Caro]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilización de los anticoagulantes orales de acción directa en Atención Primaria de España. Posicionamiento de SEMERGEN ante la situación actual]]></article-title>
<source><![CDATA[Semergen]]></source>
<year>2019</year>
<volume>45</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>413-49</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nuin Villanueva]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Arroyo Aniés]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yurss Arruga]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Granado Hualde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo Herrado]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del programa piloto de descentralización del control del tratamiento anticoagulante oral en el Servicio Navarro de Salud-Osasunbidea]]></article-title>
<collab>Elía Pitillas F et al</collab>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2005</year>
<volume>124</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>326-31</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso Roca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Barroso Muñoz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Solanes]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Alcaraz Bethancourt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Puche López]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gordillo López]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Situación actual del control de la anticoagulación oral en atención primaria]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>1999</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>127-33</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Zyl]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wysokinski]]></surname>
<given-names><![CDATA[WE]]></given-names>
</name>
<name>
<surname><![CDATA[Jaeger]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Casanegra]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Gersh]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In-home Compared with In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves A Population-Based Study]]></article-title>
<collab>McBane RD et al</collab>
<source><![CDATA[Mayo Clin Proc Innov Qual Outcomes]]></source>
<year>2020</year>
<volume>4</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>511-20</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Altirriba]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Aparicio]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral anticoagulation in primary care]]></article-title>
<source><![CDATA[Rev Esp Sanid Penit]]></source>
<year>2017</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19-34</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siddiqui]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[DeRemer]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Waller]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Gujral]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin]]></article-title>
<source><![CDATA[J Innov Card Rhythm Manag]]></source>
<year>2018</year>
<volume>9</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3428-34</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keeling]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Baglin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Tait]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Watson]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Perry]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines on oral anticoagulation with warfarin - Fourth edition]]></article-title>
<collab>Baglin C et al</collab>
<source><![CDATA[Br J Haematol]]></source>
<year>2011</year>
<volume>154</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>311-24</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguirre Rodríguez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Grado de control de la Anticoagulación con antagonistas de la vitamina K en Atención Primaria Estudio GRANADA]]></article-title>
<collab>Jiménez de la Cruz M.Hidalgo Rodríguez A</collab>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2017</year>
<volume>148</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>571-2</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aguirre Rodríguez]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo Rodríguez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anticoagulation Quality Control in Primary Care with Vitamin K Antagonist]]></article-title>
<collab>Jiménez de la Cruz M.Alonso Ródenas M.Mené Llorente M.Alfonso Zamora I</collab>
<source><![CDATA[J Health Sci Educ]]></source>
<year>2017</year>
<volume>1</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Criterios y recomendaciones generales para el uso de los anticoagulantes orales directos (ACOD) en la prevención del ictus y la embolia sistémica en pacientes con fibrilación auricular no valvular. Informe de posicionamiento terapéutico]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cerdá]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cerezo-Manchado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Johansson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation outcomes from the first observational and prospective study in a Spanish population]]></article-title>
<collab>Varela A et al</collab>
<source><![CDATA[J Comp Eff Res]]></source>
<year>2019</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>165-78</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anguita Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bertomeu Martínez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Calidad de la anticoagulación con antagonistas de la vitamina K en España prevalencia de mal control y factores asociados]]></article-title>
<collab>CequierFillat A et al</collab>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2015</year>
<volume>68</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>761-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Declaración de Helsinki de la Asociación Médica Mundial]]></article-title>
<source><![CDATA[Principios éticos para las investigaciones médicas en seres humanos]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Brasil ]]></publisher-loc>
<publisher-name><![CDATA[Fortaleza]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boned-Ombuena]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez-Panadés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[López-Maside]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Miralles-Espí]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guardiola Vilarroig]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalencia de la anticoagulación oral y calidad de su seguimiento en el ámbito de la atención primaria estudio de la Red Centinela Sanitaria de la Comunitat Valenciana]]></article-title>
<collab>Adam Ruiz D et al</collab>
<source><![CDATA[Aten Primaria]]></source>
<year>2017</year>
<volume>49</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>534-48</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cinza-Sanjurjo]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rey-Aldana]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gestal-Pereira]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Calvo-Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del grado de anticoagulación de pacientes con fibrilación auricular en el ámbito de atención primaria de Galicia Estudio ANFAGAL]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2015</year>
<volume>68</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>753-60</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández López]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[López Ramiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estado de control de pacientes en tratamiento con anticoagulantes orales antagonistas de la vitamina K en atención primaria Estudio ECOPAVIK]]></article-title>
<collab>Merino de Haro I.Cedeño Manzano G.Díaz Siles F.Hermoso Sabio A</collab>
<source><![CDATA[Semergen]]></source>
<year>2016</year>
<volume>42</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>530-7</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regueiro Martínez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Seoane Suárez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Allegue Cortez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluación del grado de control del tratamiento anticoagulante oral en atención primaria. Estudio TAOVI]]></article-title>
<source><![CDATA[Cad Aten Primaria (revista en Internet)]]></source>
<year>2016</year>
<page-range>19-23</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Molina Casado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Garrido Escudero]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Idígoras]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez González]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Escolar Castellón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control del tratamiento anticoagulante oral en atención primaria de la provincia de Málaga]]></article-title>
<source><![CDATA[Rev Calid Asist]]></source>
<year>2006</year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>293-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alonso Roca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa Guerrero]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Grado de control del tratamiento anticoagulante oral en los centros de Atención Primaria de la Comunidad de Madrid estudio CHRONOS-TAO]]></article-title>
<collab>Mainar de Paz V.Arribas García MP.Sánchez Perruca L.Rodríguez Barrientos R et al</collab>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2015</year>
<volume>145</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>192-7</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barrios]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Escobar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Prieto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Osorio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Polo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España Estudio PAULA]]></article-title>
<collab>Lobos JM et al</collab>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2015</year>
<volume>68</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>769-76</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ansell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hollowell]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pengo]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Brotons]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Caro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Drouet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation The international study of anticoagulation management (ISAM)]]></article-title>
<source><![CDATA[J Thromb Thrombolysis]]></source>
<year>2007</year>
<volume>23</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>83-91</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fitzmaurice]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral anticoagulation control The European perspective]]></article-title>
<source><![CDATA[J Thromb Thrombolysis]]></source>
<year>2006</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>95-100</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertomeu-González]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Anguita]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Arribas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cequier]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muñiz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quality of anticoagulation with vitamin K antagonists]]></article-title>
<collab>Castillo-Castillo J et al</collab>
<source><![CDATA[Clin Cardiol]]></source>
<year>2015</year>
<volume>38</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>357-64</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Spall]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Wallentin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Yusuf]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
<name>
<surname><![CDATA[Nieuwlaat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries An analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) Trial]]></article-title>
<collab>Yang S et al</collab>
<source><![CDATA[Circulation]]></source>
<year>2012</year>
<volume>126</volume>
<numero>19</numero>
<issue>19</issue>
<page-range>2309-16</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connolly]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pogue]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Eikelboom]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Flaker]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Commerford]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range]]></article-title>
<collab>Franzosi MG et al</collab>
<source><![CDATA[Circulation]]></source>
<year>2008</year>
<volume>118</volume>
<numero>20</numero>
<issue>20</issue>
<page-range>2029-37</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nilsson]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Grove]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[TB]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Skjøth]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sex differences in treatment quality of self-managed oral anticoagulant therapy 6,900 patient-years of follow-up]]></article-title>
<collab>Maegaard M et al</collab>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
